Tenaya Therapeutics, Inc. (TNYA) 股票分析

公司概述

Tenaya Therapeutics, Inc. operates as a clinical-stage biotechnology entity dedicated to discovering, developing, and delivering targeted therapies specifically for heart disease within the United States market. The company functions within the Healthcare sector, more precisely categorized under the Biotechnology industry, which implies a focus on late-stage research and development rather than established commercial revenue streams. Currently, the enterprise employs approximately 70 staff members and maintains a market capitalization of $157.37 million. The absence of reported annual revenue figures combined with the current market cap suggests that the company's valuation is derived primarily from the potential future value of its pipeline, specifically its lead product candidate, TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy currently in Phase 1b/2 trials.

财务健康

The financial statements reveal a Net Income of $-90,597,000 over the trailing twelve months, with an EBITDA of $-84,895,000, while reported revenue is not available for the trailing twelve months. The significant discrepancy between the reported net income loss and the EBITDA loss highlights the substantial impact of non-operating expenses, such as interest or tax adjustments, on the bottom line in this pre-revenue stage. Free cash flow stands at $-37,358,876, indicating a continuous consumption of cash reserves necessary to fund ongoing clinical development and operational expenditures. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting the typical accounting treatment for entities with negligible or zero sales revenue where margins are mathematically undefined or zero. The company holds $100.55 million in cash against $10.83 million in debt, resulting in a Debt to Equity ratio of 8.79. Despite the high Debt to Equity figure, the balance sheet appears conservative in terms of solvency due to the substantial cash buffer relative to the absolute debt load. Liquidity is robust, evidenced by a Current Ratio of 6.84, which indicates the company possesses ample short-term assets to cover its current liabilities without immediate refinancing risks. Return on Equity is -83.8% and Return on Assets is -43.7%, metrics that reveal management is currently generating losses on the capital deployed rather than positive returns, a common characteristic of clinical-stage biotechs before product approval.

估值评估

Trailing P/E and Forward P/E metrics present a complex picture with a Forward P/E of -1.60 and a Trailing P/E marked as N/A due to the lack of positive earnings. The negative Forward P/E implies that analysts or market participants are projecting continued negative earnings in the near term, precluding traditional earnings-based valuation multiples from providing meaningful comparisons. The Price to Book ratio is 1.27, suggesting the market values the company at a slight premium over its tangible book value, potentially reflecting the intrinsic value of its intellectual property and pipeline assets. Alternative valuation metrics like Price to Sales, which is N/A, and EV/EBITDA at -0.80, further underscore that traditional multiple-based comparisons are not applicable for a firm with no sales and negative earnings. The stock has traded within a 52-week range defined by a high of $2.35 and a low of $0.36. Without a specific current price to calculate the exact percentage deviation, the trading band indicates high volatility, with the stock capable of significant swings between these extremes. The Beta is 3.00, indicating that the stock's price volatility is three times that of the broader market, meaning it experiences amplified price movements during periods of general market turbulence.

Growth & Income

Reported Revenue Growth Year-over-Year and Earnings Growth Year-over-Year are both listed as N/A, preventing a direct calculation of growth rates between revenue and earnings due to the absence of revenue data. Consequently, it is impossible to determine whether earnings are growing faster or slower than revenue as both growth metrics are unavailable for calculation. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, which indicates that all available earnings, however negative, are retained within the company or that no dividends are distributed given the lack of distributable income. The overall growth and income profile is characterized by a lack of current income generation, with the company relying entirely on retained cash reserves and external capital to finance its high-risk development activities rather than distributing returns to shareholders or demonstrating historical revenue expansion.